DGAP-News

STADA Arzneimittel AG: Nine-month results show strong development in the third quarter - outlook for 2015 confirmed

DGAP-News: STADA Arzneimittel AG / Key word(s): Miscellaneous
STADA Arzneimittel AG: Nine-month results show strong development in
the third quarter - outlook for 2015 confirmed

12.11.2015 / 07:25

---------------------------------------------------------------------

Important items at a glance
- Group sales rises by 3 percent - adjusted +6 percent
- Sales increase in Central Europe (+5 percent), Asia/Pacific & MENA
(+62 percent), CIS/Eastern Europe in local currency (+16 percent) -
Russia in local currency (+18 percent) - Germany (+1 percent)
- Adjusted EBITDA declines by 7 percent
- Adjusted net income decreases by 7 percent
- Outlook for 2015 confirmed

STADA key figures

                             1-9/2015             1-9/2014             +/-

Group sales                  Euro 1,533.5 million Euro 1,482.7 million +3%

EBITDA, reported             Euro 281.2 million   Euro 293.6 million   -4%

EBITDA adjusted              Euro 293.8 million   Euro 316.2 million   -7%

Net income, reported         Euro 89.9 million    Euro 99.1 million    -9%

Net income, adjusted         Euro 126.9 million   Euro 136.1 million   -7%

Earnings per share, reported Euro 1.46            Euro 1.64            -11%

Earnings per share, adjusted Euro 2.07            Euro 2.25            -8%

Bad Vilbel, November 12, 2015 - In the first nine months of 2015, the STADA
Group achieved pleasing increases in sales in the two market regions
Central Europe and Asia/Pacific & MENA. Although STADA continued to be
faced with difficult framework conditions in the market region CIS/Eastern
Europe, it was also able to achieve a sales increase in local currency. As
regards one-time special effects, a total amount of Euro 13.7 million
before or Euro 13.6 million after taxes was reported in connection with
currency translation expenses recorded in the income statement as a result
of the weak Russian ruble, the strong devaluation of the Ukrainian hryvnia
and an extremely weak Kazakhstani tenge.

"Overall, we are pleased with the business development of STADA in the
first nine months of 2015. Despite continued difficult framework conditions
in the market region CIS/Eastern Europe, the key earnings figures decreased
less than we had originally expected due to a robust development in the
other market regions, among other things", says Hartmut Retzlaff, Chairman
of the Executive Board at STADA Arzneimittel AG.

Development of sales
Group sales increased by 3 percent to Euro 1,533.5 million in the first
nine months of 2015 (1-9/2014: Euro 1,482.7 million).

Sales of the core segment Generics in the reporting period recorded a